Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus POLYCILLIN PRB.
PENICILLIN-2 vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic